Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Use of Dexamethasone Given to Sibling Donors as a Way of In Vivo Purging of Allo Reactive Donor T Cells in rhg-CSF Mobilized Peripheral Blood Stem Cell Transplantations Resulted in Significant Decrease in CD3+ Cells and Increased CD34+ Yield.

Khaleel K. Ashraf, MD, Arabella B. Tilden, PhD, Yufeng Li, PhD, Lawrence Lamb, PhD, Donna E. Salzman, MD, Matthew H. Carabasi, MD, Richard Lopez, MD, William P. Vaughan, MD

Blood (2007) 110 (11): 3047.

https://doi.org/10.1182/blood.V110.11.3047.3047

Published: 2007

Journal Articles

ASBMT Risk Group and CD 34+ Dose Predicted for the Development of aGVHD in Allogeneic MRD Transplants When the Donors Who Received a Combined Mobilization and In Vivo TCD Regimen Using rhg-CFS and Dexamethasone.

Khaleel K. Ashraf, MD, Arabella B. Tilden, PhD, Yufeng Li, PhD, Sameer Gupta, MD, Lawrence S. Lamb, PhD, Donna E. Salzman, MD, Richard Lopez, MD, William P. Vaughan, MD

Blood (2007) 110 (11): 5006.

https://doi.org/10.1182/blood.V110.11.5006.5006

Published: 2007

Journal Articles

Improving Dosing Precision in Buslfan (BU) Based Preparative Regimens for Hematopoietic Stem Cell Transplantation (HSCT).

William P. Vaughan, MD, Amy G. Nance, CRNP, Donna E. Salzman, MD

Blood (2004) 104 (11): 1148.

https://doi.org/10.1182/blood.V104.11.1148.1148

Published: 2004

Journal Articles

Improved Outcomes of Autologous (Auto) Hematopoeitic Stem Cell Transplantation (HSCT) for Intermediate and High Risk (I/HR) Aggressive (AG) Non Hodgkin Lymphoma (NHL) with IV vs PO Busulfan (Bu) in a Bu, Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen.

Charu Aggarwal, MBBS, Sameer Gupta, MBBS, Donna E. Salzman, MD, Amy G. Dickey, CRNP, William P. Vaughan, MD

Blood (2004) 104 (11): 1881.

https://doi.org/10.1182/blood.V104.11.1881.1881

Published: 2004

Journal Articles

Decreased Acute but Not Chronic Graft Versus Host Disease (GVHD) after Allogeneic (ALLO) Hematopoietic Stem Cell Transplant (HSCT) from Matched Sibling Donors (MRD) Using Peripheral Blood Progenitor Cells (PBPC) Mobilized with Filgastrim (GCSF) Plus Dexamethasone (DEX).

Sameer Gupta, MBBS, Arabella B. Tilden, PhD, William P. Vaughan, MD, Donna E. Salzman, MD, Lawrence S. Lamb, PhD, Rhonda O. Katz, CRNP, Matthew H. Carabasi, MD

Blood (2004) 104 (11): 3342.

https://doi.org/10.1182/blood.V104.11.3342.3342

Published: 2004

Journal Articles

Fatal sickle cell crisis after granulocyte colony-stimulating factor administration

Brian K. Adler, Donna E. Salzman, Matthew H. Carabasi, William P. Vaughan, Vishnu V. B. Reddy, Josef T. Prchal

Blood (2001) 97 (10): 3313–3314.

https://doi.org/10.1182/blood.V97.10.3313

Published: 2001

NARROW

Use of Dexamethasone Given to Sibling Donors as a Way of In Vivo Purging of Allo Reactive Donor T Cells in rhg-CSF Mobilized Peripheral Blood Stem Cell Transplantations Resulted in Significant Decrease in CD3+ Cells and Increased CD34+ Yield.

ASBMT Risk Group and CD 34+ Dose Predicted for the Development of aGVHD in Allogeneic MRD Transplants When the Donors Who Received a Combined Mobilization and In Vivo TCD Regimen Using rhg-CFS and Dexamethasone.

Improving Dosing Precision in Buslfan (BU) Based Preparative Regimens for Hematopoietic Stem Cell Transplantation (HSCT).

Improved Outcomes of Autologous (Auto) Hematopoeitic Stem Cell Transplantation (HSCT) for Intermediate and High Risk (I/HR) Aggressive (AG) Non Hodgkin Lymphoma (NHL) with IV vs PO Busulfan (Bu) in a Bu, Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen.

Decreased Acute but Not Chronic Graft Versus Host Disease (GVHD) after Allogeneic (ALLO) Hematopoietic Stem Cell Transplant (HSCT) from Matched Sibling Donors (MRD) Using Peripheral Blood Progenitor Cells (PBPC) Mobilized with Filgastrim (GCSF) Plus Dexamethasone (DEX).

Fatal sickle cell crisis after granulocyte colony-stimulating factor administration

Email alerts

ASH Publications

American Society of Hematology

Use of Dexamethasone Given to Sibling Donors as a Way of In Vivo Purging of Allo Reactive Donor T Cells in rhg-CSF Mobilized Peripheral Blood Stem Cell Transplantations Resulted in Significant Decrease in CD3+ Cells and Increased CD34+ Yield.

ASBMT Risk Group and CD 34+ Dose Predicted for the Development of aGVHD in Allogeneic MRD Transplants When the Donors Who Received a Combined Mobilization and In Vivo TCD Regimen Using rhg-CFS and Dexamethasone.

Improving Dosing Precision in Buslfan (BU) Based Preparative Regimens for Hematopoietic Stem Cell Transplantation (HSCT).

Improved Outcomes of Autologous (Auto) Hematopoeitic Stem Cell Transplantation (HSCT) for Intermediate and High Risk (I/HR) Aggressive (AG) Non Hodgkin Lymphoma (NHL) with IV vs PO Busulfan (Bu) in a Bu, Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen.

Decreased Acute but Not Chronic Graft Versus Host Disease (GVHD) after Allogeneic (ALLO) Hematopoietic Stem Cell Transplant (HSCT) from Matched Sibling Donors (MRD) Using Peripheral Blood Progenitor Cells (PBPC) Mobilized with Filgastrim (GCSF) Plus Dexamethasone (DEX).

Fatal sickle cell crisis after granulocyte colony-stimulating factor administration

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only